Table 1 Features of the study population for sequencing analysis and validation by group.
Variable | Meta-transcriptome sequencing analysis | |||
|---|---|---|---|---|
Controls (n = 10) | AH (n = 10) | Gout (n = 6) | p | |
Age (years) | ||||
Average (± SD) | 42.7 (± 7.69) | 41.22 (± 8.45) | 45.67 (± 11.55) | 0.65* |
BMI (kg/m2) | ||||
Median (IQR) | 25.48 (3.30) | 27.04 (1.97) | 24.88 (3.18) | 0.29** |
Urate (mg/dL) | ||||
Average (± SD) | 5.63 (± 0.71) | 8.43 (± 1.87) | 8.29 (± 1.43) | < 0.01* |
Glucose (mg/dL) | ||||
Median (IQR) | 89.47 (15.37) | 94.44 (14.10) | 93.70 (16.08) | 0.72** |
Triglycerides (mg/dL) | ||||
Median (IQR) | 155.91 (22.08) | 125.68 (42.94) | 187.20 (96.32) | 0.01** |
Cholesterol (mg/dL) | ||||
Average (± SD) | 148.39 (± 46.48) | 150.82 (± 31.87) | 149.41 (± 39.59) | 0.99* |
Disease duration (years) | ||||
Median (IQR) | NA | NA | 6.0 (4.0) | NA |
Tophus (%) | 0 | 0 | 6 (100) | NA |
Hypouricemic treatment (%) | ||||
Alopurinol | 0 | 0 | 6 (100) | NA |
